| Autor: |
Daiki Nakashima, Tsuguhisa Nakayama, Syunsuke Minagawa, Tetsuya Adachi, Chieko Mitsuyama, Yoko Shida, Tsuneya Nakajima, Shin-ichi Haruna, Yoshinori Matsuwaki |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Allergology International, Vol 72, Iss 4, Pp 557-563 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1323-8930 |
| DOI: |
10.1016/j.alit.2023.03.007 |
| Popis: |
Background: Eosinophilic otitis media (EOM) is a refractory condition associated with eosinophilic chronic rhinosinusitis and bronchial asthma. EOM is characterized by type-2 inflammation and is refractory to various treatments. We investigated the efficacy of dupilumab, interleukin-4 receptor alpha antagonist, for patients with EOM complicated by eosinophilic chronic rhinosinusitis (ECRS). Methods: Between April 2017 and April 2022, we treated 124 patients with dupilumab for refractory CRS or bronchial asthma. Of these, 14 had EOM concurrently, and 10 of them who had been treated for >6 months were included in our study. We retrospectively evaluated the efficacy of dupilumab by the amount of systemic corticosteroid used, the frequency of exacerbations, severity score of EOM, computed tomography (CT) score of temporal bones, and pure tone audiometry. We also enrolled 8 EOM patients without dupilumab treatment as a control group. Results: Dupilumab significantly improved the amount of systemic corticosteroid used and the frequency of exacerbation and compared with before dupilumab was used (p = 0.01 and |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
